Seven Researchers Guilty of Misconduct in Macchiarini Case

The Karolinska Institute’s latest decision includes a guilty verdict for one of the whistleblowers who contributed to the investigation.

Jun 25, 2018
Catherine Offord

Italian thoracic surgeon Paolo Macchiarini and six of his colleagues, one of whom was a whistleblower, have been found guilty of scientific misconduct in the latest investigation into the infamous researcher’s work by his former institution, the Karolinska Institute in Sweden. In a statement published yesterday (June 25), the Institute announced that an analysis of six articles published across four journals had discovered inaccuracies, misleading information, data fabrication, unjustified treatments, and a lack of appropriate ethical approvals. An additional 31 authors were deemed “blameworthy” for their contributions to the publications.

“This decision has been made after careful investigations in a case that has had major impact on Karolinska Institutet, on the scientific community at large, and on public confidence in medical research,” the Karolinska Institute’s president, Ole Petter Ottersen, says in the statement. “In particular, the case has had tragic consequences for patients and their relatives, for which I am deeply sorry. Karolinska Institutet will now continue to implement the measures that are necessary to prevent something like this from happening again.”

See “Girl with Synthetic Trachea Dies

Macchiarini’s research centered on a radical approach to tracheal transplantation that involved seeding bioengineered windpipes with a patient’s own stem cells. His work became the subject of multiple investigations following the deaths of several patients, along with allegations of ethical oversights and data fabrication. 

See “Karolinska Finds Macchiarini Guilty of Misconduct

Macchiarini himself was found guilty of scientific misconduct by the Karolinska Institute (KI) at the end of 2016, along with three coauthors, following an investigation relating to a paper published in Nature Communications in 2014. That paper was retracted in March, 2017. The latest announcement by the institution requests the retraction of all six articles examined in the investigation, all of which were published between 2011 and 2014, mirroring recommendations made by Sweden’s Central Ethics Review Board after its own investigation in 2017. 

See “Swedish Ethics Review Board: Macchiarini is Guilty

A spokesperson for The Lancet, where two of the papers were published, tells Retraction Watch, “We welcome the report from the Karolinska Institute. We will study their findings and conclusions carefully and respond as soon as possible.”

Regarding the decision to find one of the four whistleblowers guilty of misconduct, Ottersen notes that “it is KI’s firm opinion that a whistle blower who has participated in a scientific study and also as author of a scientific article, despite reporting, cannot be freed from blame or absolved from responsibility.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!